Vera Health closed a $28.5M Series A on October 27, with Threshold Ventures in the lead and Optum Ventures, Mantis VC and SV Angel joining. Y Combinator and Gradient both raised their commitments, lifting the firm’s lifetime total to $32M.
What Vera sells is a clinical search engine built to reason the way a physician does, then display its working. Before it answers, it sweeps over 60 million publications, guidelines and drug labels, and every claim it returns is colour-coded against the strength of the underlying evidence.
That design choice carries weight. Many rare conditions have neither a randomised trial nor a formal guideline, only a case series of a few patients. Vera puts that thin evidence on the screen and labels it thin, instead of handing back an answer that sounds equally confident.
Where the idea came from
Maxime Allouch, a French entrepreneur and investor, built the first version with Taieb Bennani, who is Moroccan, for their fathers, both practising doctors. Those two users have since turned into 800,000 clinicians working in 190 countries, including roughly one in four doctors in Spain.
The paperwork is in place: privacy mandates on both sides of the Atlantic, HIPAA here and GDPR in Europe, are met, alongside SOC 2 Type II.
Why investors are paying attention
Somewhere in the world a new paper lands in the medical literature roughly every 20 seconds, a pace no clinician can keep up with. General-purpose chatbots will answer anyway, and hospitals have begun policing that failure mode.
Having Optum Ventures, the venture arm of UnitedHealth Group, on the cap table suggests payer-side buyers now treat graded evidence as something they want to purchase rather than a box to tick. Threshold Ventures led the round.
Vera declined to discuss revenue, named customers or hiring plans.
